Dianthus Therapeutics, Inc. (DNTH)

Dianthus Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	6.52	6.24	2.83	6.42	1.48
Revenue Growth (YoY)	102.36%	120.63%	-55.96%	334.76%	-
Gross Profit	6.52	6.24	2.83	6.42	1.48
Selling, General & Admin	26.69	24.99	18.16	6.74	1.96
Research & Development	97.03	83.11	32.84	29.38	12.61
Operating Expenses	123.72	108.1	51	36.12	14.56
Operating Income	-117.2	-101.86	-48.17	-29.71	-13.09
Interest & Investment Income	15.55	17.37	4.76	1.15	0
Currency Exchange Gain (Loss)	-0.07	-0.06	-0.09	0.14	-0.03
Other Non Operating Income (Expenses)	-0.54	-0.55	-0.06	-0.05	-
EBT Excluding Unusual Items	-102.26	-85.12	-43.56	-28.48	-13.11
Gain (Loss) on Sale of Investments	1.52	0.15	-	-	-
Pretax Income	-100.73	-84.97	-43.56	-28.48	-13.11
Net Income	-100.73	-84.97	-43.56	-28.48	-13.11
Net Income to Common	-100.73	-84.97	-43.56	-28.48	-13.11
Shares Outstanding (Basic)	36	33	5	1	4
Shares Outstanding (Diluted)	36	33	5	1	4
Shares Change (YoY)	215.78%	546.44%	489.48%	-78.17%	-
EPS (Basic)	-2.81	-2.55	-8.45	-32.57	-3.27
EPS (Diluted)	-2.81	-2.55	-8.45	-32.57	-3.27
Free Cash Flow	-90.97	-78.29	-36.97	-29.21	-9.94
Free Cash Flow Per Share	-2.54	-2.35	-7.17	-33.41	-2.48
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-1796.40%	-1633.75%	-1704.67%	-462.91%	-886.59%
Profit Margin	-1544.02%	-1362.78%	-1541.22%	-443.76%	-888.14%
Free Cash Flow Margin	-1394.33%	-1255.57%	-1308.24%	-455.18%	-673.24%
EBITDA	-117.1	-101.77	-48.11	-29.68	-
D&A For EBITDA	0.1	0.1	0.07	0.03	-
EBIT	-117.2	-101.86	-48.17	-29.71	-13.09
Revenue as Reported	6.52	6.24	2.83	-	-

Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q